Name: CRISPR THERAPEUTICS AG (CRSP) Stock
Brand: CRISPR THERAPEUTICS AG
Rating: 5 (3 reviews)

CRSP Latest News, Press Relases and Analysis

All

Press Releases

5 hours ago - By: The Motley Fool - Mentions: AAPL AVGO AMZN VRTX ...

12 Days of Investing: My Top 12 Stocks to Buy Before 2026

3 days ago - By: The Motley Fool - Mentions: VRTX SIRI

2 Healthcare Stocks to Buy Ahead of the New Year

5 days ago - By: Zacks Investment Research - Mentions: ACAD

Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?

7 days ago - By: Zacks Investment Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

12 days ago - By: Zacks Investment Research - Mentions: VRTX MRNA

Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?

a month ago - By: Stocktwits

Retail Bulls Call CRISPR ‘Criminally Undervalued’ After Gene-Editing Breakthrough Cuts Cholesterol By 70%

17 days ago - By: Zacks Investment Research - Mentions: REGN BEAM NTLA

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

24 days ago - By: Zacks Investment Research - Mentions: REGN BEAM NTLA

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

a month ago - By: Zacks Investment Research - Mentions: ILMN PACB EDIT NTLA ...

Top 3 Genomics Stocks to Consider for Your Portfolio

a month ago - By: Zacks Investment Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

a month ago - By: Zacks Investment Research - Mentions: REGN BEAM NTLA

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?

a month ago - By: Benzinga - Mentions: ARWR REGN

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

a month ago - By: Zacks Investment Research - Mentions: ALKS VRTX CRMD

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

a month ago - By: Investor's Business Daily - Mentions: AAPL NTLA

Why Gene-Editing Giants Crispr And Intellia Just Surged

a month ago - By: Zacks Investment Research - Mentions: BRTX

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

a month ago - By: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

a month ago - By: Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note

a month ago - By: Investor's Business Daily - Mentions: RY RY.CA NTLA ALNY ...

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies

a month ago - By: Zacks Investment Research - Mentions: VRTX ANIP NTLA

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

a month ago - By: Benzinga - Mentions: ADPT COIN BEAM ARKW ...

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys

a month ago - By: Zacks Investment Research - Mentions: VRTX ANIP NTLA

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

a month ago - By: Zacks Investment Research - Mentions: ANIP IMCR RXRX

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

a month ago - By: Zacks Investment Research - Mentions: VRTX BEAM NTLA

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

2 months ago - By: Zacks Investment Research

CRISPR THERAPEUTICS AG (CRSP) Stock News

CRSP Latest News, Press Relases and Analysis

12 Days of Investing: My Top 12 Stocks to Buy Before 2026

2 Healthcare Stocks to Buy Ahead of the New Year

Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?

Retail Bulls Call CRISPR ‘Criminally Undervalued’ After Gene-Editing Breakthrough Cuts Cholesterol By 70%

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

Top 3 Genomics Stocks to Consider for Your Portfolio

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

Why Gene-Editing Giants Crispr And Intellia Just Surged

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies

VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It